Boehringer Ingelheim Taiwan Ltd yesterday awarded six research teams and pharmaceutical start-ups a total of NT$5 million (US$176,398) to support their efforts in innovation as their work shows great potential for satisfying unmet medical needs, it said.
The awards are part of its parent company’s “Grass Roots Initiative” program, which enables the study of emerging science by championing early-stage life-science companies, managing director James Chiou (邱建誌) told an award ceremony in Taipei.
The six teams were selected by the company’s headquarters out of 169 companies that applied for the reward, Chiou said.
Through the program, Boehringer Ingelheim not only encourages innovation in medicine,